Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats

Pharmaceutical Research

Volumn 29, Issue 4, 2012, Pages 1143-1157

  Holm, René ^a   Kall, Morten A ^a   Frølund, Sidsel ^b   Nielsen, Andreas L ^a,b   Jensen, Anne ^b   Broberg, Mie Larsen ^b   Nielsen, Carsten Uhd ^b  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amino acids; Rectal absorption; Rectal drug delivery; SLC36A1 Slc36a1; Vigabatrin

Indexed keywords

AMINO ACID TRANSPORTER; PROLINE; PROTON COUPLED AMINO ACID TRANSPORTER HUMAN ISOFORM; PROTON COUPLED AMINO ACID TRANSPORTER MURINE ISOFORM; RNA; TRYPTOPHAN; UNCLASSIFIED DRUG; VIGABATRIN; COTRANSPORTER; PROTON; SLC36A1 PROTEIN, HUMAN; SLC36A1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG FORMULATION; DRUG RESEARCH; DRUG TRANSPORT; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RECTUM; VOLTAGE CLAMP; WESTERN BLOTTING; XENOPUS LAEVIS; ABSORPTION; ANIMAL; BIOAVAILABILITY; CELL STRAIN CACO 2; DRUG ANTAGONISM; EPITHELIUM; HUMAN; INTESTINE MUCOSA; METABOLISM; PHYSIOLOGY; RECTAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ABSORPTION; ADMINISTRATION, RECTAL; AMINO ACID TRANSPORT SYSTEMS; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; EPITHELIUM; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MALE; OOCYTES; PROLINE; PROTONS; RATS; RATS, SPRAGUE-DAWLEY; RECTUM; SYMPORTERS; TRYPTOPHAN; VIGABATRIN; XENOPUS LAEVIS;

EID: 84862669703     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0673-0     Document Type: Article

References (31)

1. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia. 2009;50:163-73.
2. Kossoff EH. Infantile spasms. Neurologist. 2010;16:69-75.
3. Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997;26:389-95.
4. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor control. Drugs. 1991;41:889-926.
5. Rey E, Pons G, Olive G. Vigabatrin - clinical pharmacokinetics. Clin Pharmacokinetics. 1992;23:267-78.
6. Perucca E. Pharmacokinetic variability of new antiepileptic drugs at different ages. Ther Drug Monit. 2005;27:714-7.
7. Valdizan EM, Armijo JA. Effect of singel and multiple increasing doses of vigabatrin on brain GABA metabolism and correlation with vigabatrin plasma concentration. Biochem Pharmacol. 1992;43:2143-50.
8. Hoke JF, Yuh L, Antony KK, Okerholm RA, Elberfeld JM, Sussman NN. Pharmacokinetics of vigabatrin following single and multiple oral doses in normal volunteers. J Clin Pharmacol. 1993;33:458-62.
9. Frisk-Holmberg M, Kerth P, Meyer P. Effect of food on the absorption of vigabatrin. Br J Pharmacol. 1989;27:S23-5.
10. Deckers CL, Knoester PD, de Haan GJ, Keyser A, Renier WO, Hekster YA. Selection criteria for the clinical use of newer antiepileptic drugs. CNS Drugs. 2003;17:405-21.
11. Henczi M, Nagy J, Weaver DF. Determination of octanol-water partition coefficients by an HPLC method for anticonvulsant structure-activity studies. J Pharm Pharmacol. 1995;47:345-7.
12. Crowe A, Teoh YK. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. J Drug Target. 2006;14:291-300.
13. Abbot EL, Grenade DS, Kennedy DJ, Gatfield KM, Thwaites DT. Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H+-coupled amino-acid transporter hPAT1. Br J Pharmacol. 2006;147:298-306.
14. Grigat S, Fork C, Bach M, Golz S, Geerts A, Schomig E, Grundemann D. The carnitine transporter SLC22A5 is not a general drug transporter, but it efficiently translocates mildronate. Drug Metab Dispos. 2009;37:330-7.
15. Anderson CM, Grenade DS, Boll M, Foltz M, Wake KA, Munck BG, Daniel H, Ganapathy V, Thwaites DT. H+/ amino acid transporter 1 (PAT1) is the imino acid carrier: an intestinal nutrient/drug transporter in human and rat. Gastroenterology. 2004;127:1410-22.
16. Metzner L, Brandsch M. Transport of pharmacologically active proline derivatives by the human proton-coupled amino acid transporter hPAT1. Eur J Pharn Biopharm. 2004;309:28-35.
17. Howard A, Goodlad RA, Walters JR, Ford D, Hirst BH. Increased expression of specific intestinal amino acid and peptide transporter mRNA in rats fed by TPN is reversed by GLP-2. J Nutr. 2004;134:2957-64.
18. Broberg ML, Holm R, Tønsberg H, Frølund S, Ewon KB, Nielsen AL, Brodin B, Jensen A, Kall MA, Christensen KV, Nielsen CU. Function and expression of the proton-coupled amino acid transporter Slc36a1 along the rat gastrointestinal tract: Implications for intestinal absorption of gaboxadol. Submitted Br J Pharmacol (2011).
19. Frolund S, Holm R, Brodin B, Nielsen CU. The proton-coupled amino acid transporter, SLC36A1 (hPAT1), transports Gly-Gly, Gly-Sar and other Gly-Gly mimetics. Br J Pharmacol. 2010;161:589-600.
20. Fousteri M, Vermeulen W, van Zeeland AA, Mullenders LH. Cockayne syndrome A and B proteins differentially regulate recruitment of chromatin remodeling and repair factors to stalled RNA polymerase II in vivo. Mol Cell. 2006;23:471-82.
21. Larsen M, Holm R, Jensen KG, Brodin B, Nielsen CU. Intestinal gaboxadol absorption via PAT1(SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol. 2009;157:1380-9.
22. Frolund S, Cutillas O, Larsen M, Brodin B, Nielsen CU. delta-aminolevulinic acid is a substrate for SLC36A1 (hPAT1). Br J Pharmacol. 2010;159:1339-53.
23. Metzner L, Dorn M, Markwardt F, Brandsch M. The orally active antihyperglycemic drug beta-guanidinopropionic acid is transported by the human proton-coupled amino acid transporter hPAT1. Mol Pharm. 2009;6:1006-11.
24. Chen Z, Fei YJ, Anderson CM, Wake KA, Miyauchi S, Huang W, Thwaites DT, Ganapathy V. Structure, function and immunolocalization of a proton-coupled amino acid transporter (hPAT1) in the human intestinal cell line Caco-2. J Physiol. 2003;546:349-61.
25. Larsen M, Holm R, Jensen KG, Sveigaard C, Brodin B, Nielsen CU. 5-Hydroxy-L-tryptophan alters gaboxadol pharmacokinetics in rats: Involvement of PAT1 and rOat1 in gaboxadol absorption and elimination. Eur J Pharm Sci. 2010;39:68-75.
26. Schneider MR, Dahlhoff M, Horst D, Hirschi B, Trulzsch K, Muller-Hocker J, Vogelmann R, Allgauer M, Gerhard M, Steininger S, Wolf E, Kolligs FT. A key role for E-cadherin in intestinal homeostasis and paneth cell maturation. PLoS ONE. 5 (2010).
27. Van Hoorde L, Braet K, Mareel M. The N-cadherin/catenin complex in colon fibroblasts and myofibroblasts. Cell Adhesion and Communication. 7:139-+(1999).
28. Jones M, Sabatini PJB, Lee FSH, Bendeck MP, Langille BL. N-cadherin upregulation and function in response of smooth muscle cells to arterial injury. Arterioscler Thromb Vasc Biol. 2002;22:1972-7.
29. Sagne C, Agulhon C, Ravassard P, Darmon M, Hamon M, El MS, Gasnier B, Giros B. Identification and characterization of a lysosomal transporter for small neutral amino acids. Proc Natl Acad Sci U S A. 2001;98:7206-11.
30. Boll M, Foltz M, Rubio-Aliaga I, Kottra G, Daniel H. Functional characterization of two novel mammalian electrogenic protondependent amino acid cotransporters. J Biol Chem. 2002;277:22966-73.
31. Wreden CC, Johnson J, Tran C, Seal RP, Copenhagen DR, Reimer RJ, Edwards RH. The H+-coupled electrogenic lysosomal amino acid transporter LYAAT1 localizes to the axon and plasma membrane of hippocampal neurons. J Neurosci. 2003;23:1265-75.